Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-C103C Monotherapy and Combination with Atezolizumab in Advanced MAGE-A4+ Cancer
NCT03973333Phase 2Withdrawn
- Sponsor
- Immunocore
- Start
- May 2019
- Primary completion
- Sep 2023
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 3
01
Overview
A Phase 2 trial of IMC-C103C in solid tumor, ovarian cancer, sponsored by Immunocore. Planned start May 2019; status: withdrawn.
02
Drugs
IMC-C103C
03
Conditions
solid tumorovarian cancer
Beyond the preview
Go deeper on NCT03973333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03973333.